Biologics for the Management of Erythrodermic Psoriasis: An Updated Review

Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fat...

Descripción completa

Detalles Bibliográficos
Autores principales: Potestio, Luca, Camela, Elisa, Cacciapuoti, Sara, Fornaro, Luigi, Ruggiero, Angelo, Martora, Fabrizio, Battista, Teresa, Megna, Matteo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408653/
https://www.ncbi.nlm.nih.gov/pubmed/37560255
http://dx.doi.org/10.2147/CCID.S407813
_version_ 1785086210788556800
author Potestio, Luca
Camela, Elisa
Cacciapuoti, Sara
Fornaro, Luigi
Ruggiero, Angelo
Martora, Fabrizio
Battista, Teresa
Megna, Matteo
author_facet Potestio, Luca
Camela, Elisa
Cacciapuoti, Sara
Fornaro, Luigi
Ruggiero, Angelo
Martora, Fabrizio
Battista, Teresa
Megna, Matteo
author_sort Potestio, Luca
collection PubMed
description Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, and tachycardia making this condition a possible life-threatening disease, particularly if appropriate treatments are not performed. In this scenario, effective and safe therapies are required. Unfortunately, the rarity of EP makes head-to-head Phase III trials challenging, leading to the lack of established guidelines for its management. Globally, conventional systemic drugs such as cyclosporine, methotrexate, and retinoids often have contraindications linked to patients’ comorbidities and have not shown a high profile of efficacy and safety. Recently, the development of biologic drugs including anti-tumor necrosis factor-α and anti-interleukin 12–23, 23, and 17 has revealed favorable results for the management of plaque psoriasis, making them also a possible therapeutic option for EP disease. However, their use in EP is still off-label. The aim of our study was to review current literature on the use of biologic drugs for the treatment of EPs in order to offer a wide perspective on their possible application in EP management.
format Online
Article
Text
id pubmed-10408653
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-104086532023-08-09 Biologics for the Management of Erythrodermic Psoriasis: An Updated Review Potestio, Luca Camela, Elisa Cacciapuoti, Sara Fornaro, Luigi Ruggiero, Angelo Martora, Fabrizio Battista, Teresa Megna, Matteo Clin Cosmet Investig Dermatol Review Erythrodermic psoriasis (EP) is a severe and rare variant of psoriasis (less than 3% of cases), characterized by generalized scaling and erythema affecting more than 90% of body surface area. Several systemic symptoms can be present in patients with EP such as lymphadenopathy, arthralgia, fever, fatigue, dehydration, serum electrolyte disturbances, and tachycardia making this condition a possible life-threatening disease, particularly if appropriate treatments are not performed. In this scenario, effective and safe therapies are required. Unfortunately, the rarity of EP makes head-to-head Phase III trials challenging, leading to the lack of established guidelines for its management. Globally, conventional systemic drugs such as cyclosporine, methotrexate, and retinoids often have contraindications linked to patients’ comorbidities and have not shown a high profile of efficacy and safety. Recently, the development of biologic drugs including anti-tumor necrosis factor-α and anti-interleukin 12–23, 23, and 17 has revealed favorable results for the management of plaque psoriasis, making them also a possible therapeutic option for EP disease. However, their use in EP is still off-label. The aim of our study was to review current literature on the use of biologic drugs for the treatment of EPs in order to offer a wide perspective on their possible application in EP management. Dove 2023-08-04 /pmc/articles/PMC10408653/ /pubmed/37560255 http://dx.doi.org/10.2147/CCID.S407813 Text en © 2023 Potestio et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Potestio, Luca
Camela, Elisa
Cacciapuoti, Sara
Fornaro, Luigi
Ruggiero, Angelo
Martora, Fabrizio
Battista, Teresa
Megna, Matteo
Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
title Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
title_full Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
title_fullStr Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
title_full_unstemmed Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
title_short Biologics for the Management of Erythrodermic Psoriasis: An Updated Review
title_sort biologics for the management of erythrodermic psoriasis: an updated review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408653/
https://www.ncbi.nlm.nih.gov/pubmed/37560255
http://dx.doi.org/10.2147/CCID.S407813
work_keys_str_mv AT potestioluca biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT camelaelisa biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT cacciapuotisara biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT fornaroluigi biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT ruggieroangelo biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT martorafabrizio biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT battistateresa biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview
AT megnamatteo biologicsforthemanagementoferythrodermicpsoriasisanupdatedreview